Small Molecules
17 August 2015
SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus14 August 2015
Catabasis Pharmaceuticals Announces Positive Top-line Phase 1 Data for Hypercholesterolemia Product Candidate CAT-205413 August 2015
Neuropore Therapies Commences Phase 1 Clinical Trials12 August 2015
G1 Therapeutics Announces Initiation of Two Phase 1b/2a Trials of CDK4/6 Inhibitor G1T28 in Small-Cell Lung Cancer11 August 2015
Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders10 August 2015
Antibe Announces Completion of Phase I Studies of ATB-346 and an Update on Its Validation Studies10 August 2015
ARIAD Announces First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib)7 August 2015
Symbiomix Therapeutics’ First Pivotal Trial Results for SYM-1219 for Bacterial Vaginosis Presented at IDSOG6 August 2015
InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)4 August 2015
Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation4 August 2015
Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston’s Second Product, CL-H1TNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports